Qual é o preço para Sigilon Therapeutics, Inc. (SGTX)

O preço para Sigilon Therapeutics, Inc. (SGTX) é $22.47

Qual é a capitalização de mercado para Sigilon Therapeutics, Inc. (SGTX)

A capitalização de mercado para Sigilon Therapeutics, Inc. (SGTX) é $49.76M

Sigilon Therapeutics, Inc. (SGTX) Índice P/L

Cambridge, Massachusetts-based Sigilon Therapeutics, Inc., established in 2015, functions as a clinical-stage biotechnology firm dedicated to creating lasting solutions for patients grappling with chronic health conditions. Its primary investigational therapy, SIG-001, is currently undergoing Phase I/II clinical assessment to prevent bleeding episodes in individuals suffering from moderate to severe Hemophilia A. The company's research pipeline also encompasses SIG-005, designed to address the non-neurological symptoms associated with mucopolysaccharidosis type 1; SIG-007, engineered to ensure a continuous and sustained delivery of functional enzymes sufficient to generate clinical improvements and halt the advancement of Fabry disease; and SIG-002, an initiative focused on replacing islet cells for the treatment of Type 1 Diabetes. Furthermore, Sigilon Therapeutics holds a collaborative research and licensing agreement with Eli Lilly and Company for the advancement and market release of SLTx product candidates targeting Type 1 Diabetes. Originally known as Sigilon, Inc., the company officially adopted its current name in June 2017.

Ano	Índice P/E	Alterar
Não há dados suficientes para as datas fornecidas.

Ano

Índice P/E

Alterar

Não há dados suficientes para as datas fornecidas.

Empresa	Rácio P/E	Diferença do rácio P/E	País
Vertex Pharmaceuticals Incorporated VRTX.US	29.20	-	US
Argenx SE ARGX.US	30.62	-	NL
CSL Limited CSL.AX	32.46	-	AU
Lonza Group AG LONN.SW	-	-	CH
Moderna, Inc. MRNA.US	-7.93	-	US

Empresa

Rácio P/E

Diferença do rácio P/E

País